FindTrial
Sign In

DA-EPOCH-R

DRUG5 trials

Sponsors

Kanagawa Clinical Oncology study Group, Fudan University, Pharmacyclics LLC., Dana-Farber Cancer Institute, Nordic Lymphoma Group

Conditions

C-MYC positive diffuse large B-cell lymphomaDiffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedDiffuse Large B-cell LymphomaLymphoma, Large B-Cell, DiffuseRichter Syndrome

Phase 1

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
CompletedNCT02142049
Pharmacyclics LLC.Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed
Start: 2014-05-31End: 2017-08-31Updated: 2019-02-05

Phase 2

Dose-adjusted EPOCH-R in MYC Positive DLBCL
TerminatedNCT01914718
Fudan UniversityDiffuse Large B-cell Lymphoma
Start: 2013-02-28End: 2017-12-31Target: 26Updated: 2014-08-20
A Phase II trial of Dose adjusted EPOCH and Rituximab therapy for newly-diagnosed DLBCL with C-MYC rearrangement
Active, not recruitingJPRN-UMIN000015972
Kanagawa Clinical Oncology study GroupC-MYC positive diffuse large B-cell lymphoma
Start: 2014-12-01Target: 34Updated: 2026-06-29
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
Active, not recruitingNCT03054896
Dana-Farber Cancer InstituteRichter Syndrome
Start: 2017-03-08End: 2027-12-01Updated: 2026-07-10
Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis
Active, not recruitingNCT03293173
Nordic Lymphoma GroupLymphoma, Large B-Cell, Diffuse
Start: 2017-08-04End: 2024-12-31Target: 120Updated: 2024-06-21

Related Papers

Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas.
2024-04-041 citations
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter Syndrome
Hematological Oncology2023-06-0123 citations
P651: VENETOCLAX-BASED TREATMENT OF PATIENTS WITH RICHTER SYNDROME: OUTCOMES FROM A MULTICENTER RETROSPECTIVE STUDY
HemaSphere2022-06-017 citations
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome
Blood2021-11-1772 citations
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*
Leukemia & lymphoma/Leukemia and lymphoma2021-04-157 citations
A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.
Journal of Clinical Oncology2020-05-2012 citations
INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE‐ADJUSTED R‐EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC‐043)
Hematological Oncology2019-06-015 citations